India, May 28 -- InflaRx N.V. (IFRX), a German biopharmaceutical company focused on anti-inflammatory therapeutics, announced Wednesday that the Independent Data Monitoring Committee or IDMC conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum or PG recommended to stop the trial due to futility.
InflaRx said it intends to discontinue further development of vilobelimab in the PG indication and to prioritize its resources on INF904. The company expects Phase 2a data readouts in chronic spontaneous urticaria or CSU and hidradenitis suppurativa or HS this summer.
The company is also considering additional cost savings and redirection of resources toward the goal of extending its existing cash...